A CDC advisory committee will meet June 27 to vote on recommendations for the vaccine. The FDA has approved Merck’s 21-valent pneumococcal vaccine, which is specifically made for adults, the ...

The FDA's approval is partly based on Merck's late-stage trial called STRIDE-3 that pitted the vaccine against Pfizer's Prevnar 20 in adults 18 and up who had not previously received a ...

Monday, the FDA approved Merck & Co Inc’s (NYSE: MRK) Capvaxive (Pneumococcal 21-valent Conjugate Vaccine) to protect against 21 strains of bacteria to prevent a severe form of pneumococcal disease.

The Food and Drug Administration (FDA) has approved pharmaceutical company Merck’s (NYSE:MRK) new vaccine, Capvaxive. This pneumococcal conjugate vaccine is designed to prevent invasive disease ...

T he Food and Drug Administration on Monday approved Merck’s new pneumococcal vaccine for adults 18 and older.. The vaccine, which will be sold under the name Capvaxive, is designed to protect ...

FDA Approves New Vaccine From Sanofi, Merck. ByBruce Y. Lee, Senior Contributor. Forbes contributors publish independent expert analyses and insights.

The Food and Drug Administration approved Merck's vaccine designed to protect adults from a bacteria known as pneumococcus that can cause serious illnesses and a lung infection called pneumonia ...

The FDA has approved Merck's Capvaxive, the first pneumococcal conjugate vaccine for adults, protecting against 21 strains of bacteria. Additionally, Merck's Keytruda received FDA approval for ...